215
Table 2
Relationship between ETO, ceranib-2 (C-2), PRE NPs, PREC-2, doses, and
% cell viability of cervical adenocarcinoma (Hela) cell line
Sample no.
Treatment
Dose (μM)
Viability
(%)
S1
CNT (DMOS)
100
100
S2
ETO
50
60
S3
Pure ceranib-2
10
32
S4
Pure ceranib-2
25
30
S5
Pure ceranib-2
50
27
S6
Pure ceranib-2
100
20
S7
PRE NPs
0.66
78
S8
PRE NPs
0.33
89
S9
PRE NPs
0.151
81
S10
PREC-2 NPs
0.66
56
S11
PREC-2 NPs
0.33
80
S12
PREC-2 NPs
0.151
85
Table 3
The relationship between ETO, ceranib-2 (C-2), PRE NPs, PREC-2, doses,
and % cell viability of Dukes’ type B colorectal adenocarcinoma cell line
(SW480)
Sample no.
Treatment
Dose (μM)
Viability
(%)
S1
CNT (DMOS)
100
100
S2
ETO
50
60
S3
Pure ceranib-2
10
33
S4
Pure ceranib-2
25
30
S5
Pure ceranib-2
50
28
S6
Pure ceranib-2
100
20
S7
PRE NPs
0.66
78
S8
PRE NPs
0.33
80
S9
PRE NPs
0.151
82
S10
PREC-2 NPs
0.66
55
S11
PREC-2 NPs
0.33
80
S12
PREC-2 NPs
0.151
84
Antitumor Efficacy of Ceranib-2 with Nano-Formulation of PEG and Rosin Esters